AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A compound of the formula I



I

wherein R_1 independently represents one or more, same or different substituents selected from the group consisting of halogen, hydroxy, mercapto, trifluoromethyl, amino, (C_1-C_3)alkyl, (C_2-C_3)olefinic group, (C_1-C_3)alkoxy, (C_1-C_3)alkylthio, (C_1-C_6)alkylamino, (C_1-C_3)alkoxycarbonyl, cyano, carbamoyl, phenyl and nitro, provided that when R_1 represents one substituent, it is in the ortho position, and when R_1 represents more than one substituent, at least one R_1 substituent is in the ortho position; R_2 is one substituent in the ortho position, said substituent being selected from the group consisting of ~~hydrogen,~~ halogen, hydroxy, mercapto, trifluoromethyl, amino, (C_1-C_3)alkyl, (C_2-C_3)olefinic group, (C_1-C_3)alkoxy, (C_1-C_3)alkylthio, (C_1-C_6)alkylamino, (C_1-C_3)alkoxycarbonyl, cyano, carbamoyl, phenyl and nitro;

R_3 represents hydrogen, halogen, hydroxy, mercapto, trifluoromethyl, amino, (C_1-C_3)alkyl, (C_2-C_3)olefinic group, (C_1-C_3)alkoxy, (C_1-C_3)alkylthio, (C_1-C_6)alkylamino, (C_1-C_3)alkoxycarbonyl, phenyl, cyano, carboxy, or carbamoyl;

R_4 represents hydrogen, (C_1-C_3)alkyl, or allyl;

Q represents a bond, $-SO_2-$, or $-C(R_6)(R_7)(-O-C=O)-$, in which formula R_6 and R_7 independently represent hydrogen, trifluoromethyl, or (C_1-C_4)alkyl;

Y represents (C_1-C_{15})alkyl, (C_2-C_{15})olefinic group, (C_3-C_{10})carbocyclic group, or phenyl, any of which is optionally substituted by one or more, same or different substituents represented by the formula R_5; or Y represents a group of formula $-(Z-O)_n-Z$, where Z is a (C_1-C_3)alkyl and n is an integer > 1, and no continuous linear sequence of atoms in the group Y exceeds 15;

R_5 represents halogen, hydroxy, mercapto, trifluoromethyl, (C_1-C_4)alkyl, amino, (C_1-C_3)alkoxy, (C_1-C_3)alkylthio, $(C_1-$

C_6)alkylamino, (C_1-C_3)alkoxycarbonyl, cyano, azido, nitro, -COOH, -$CONH_2$, -CONHR', or -CONRR' wherein R and R' stands for (C_1-C_3)alkyl;

X represents oxygen or sulphur,

or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof.

2. (Currently Amended) A compound according to claim 1 wherein independently

- R_1 represents one or more, same or different substituents selected from the group consisting of fluoro, chloro, bromo, hydroxy, trifluoromethyl, amino, (C_1-C_2)alkyl, (C_2-C_3)alkenyl, (C_1-C_3)alkoxy, (C_1-C_3)alkoxycarbonyl, or cyano.

- R_2 represents one or more, same or different substituents selected from the group consisting of ~~hydrogen,~~ fluoro, chloro, bromo, hydroxy, trifluoromethyl, amino, (C_1-C_2)alkyl,

(C_2-C_3)alkenyl, (C_1-C_3)alkoxy.

- R_3 represents one or more, same or different substituents selected from the group consisting of hydrogen, fluoro, chloro, bromo, hydroxy, trifluoromethyl, (C_1-C_3)alkyl, (C_2-C_3)alkenyl, (C_1-C_3)alkoxy, (C_1-C_3)alkoxycarbonyl, cyano, or carboxy.

- R_4 represents hydrogen, (C_1-C_2)alkyl, or allyl.

- X represents oxygen.

- Q represents a bond or $-SO_2-$.

Y represents (C_1-C_6)alkyl; (C_2-C_6)alkenyl; (C_3-C_6)cycloalkyl; (C_5-C_8)cycloalkene group; or phenyl; any of which is optionally substituted by one or more, same or different substituents selected from the group consisting of the formula R_5, R_5 representing fluoro, chloro, bromo, hydroxy, amino, (C_1-C_2)alkoxy, (C_1-C_4)alkylamino, (C_1-C_3)alkoxycarbonyl, cyano, azido, -COOH, $-CONH_2$, -CONHR', or -CONR'R' wherein R' represents (C_1-C_2)alkyl.

3. (Previously Presented) A compound according to claim 1 or 2 wherein R_1 represents one or more, same or different substituents selected from the group consisting of fluoro, chloro, bromo, hydroxy, methyl, or methoxy.

4. (Previously Presented) A compound according to claim 1, wherein R_1 is methyl and R_2 is Cl.

5. (Previously Presented) A compound according to claim 1 selected from the group consisting of
1-Cyclohexyl-3-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino] phenyl]urea (Compound 101),
1-Ethyl-3-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]urea (Compound 102),
1-[2-[3-Chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]-3-phenylurea (Compound 103),
1-Butyl-3-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]urea (Compound 104),
1-[2-[3-Chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]-3-*iso*-propylurea (Compound 108),
1-[2-[3-Chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]-3-propylurea (Compound 109),
1-Methyl-3-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]

phenyl]urea (Compound 110),

1-Ethyl-3-[5-bromo-2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]

phenyl]urea (Compound 112),

1-Ethyl-3-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]-5-fluoro-

phenyl]urea (Compound 114),

1-Ethyl-3-[5-bromo-2-[3-chloro-4-(2,5-dimethylbenzoyl)-

phenylamino]phenyl]urea (Compound 117),

1-Ethyl-3-[5-bromo-2-[3-chloro-4-(4-chloro-2-methylbenzoyl)-

phenylamino]phenyl]urea (Compound 121),

1-Ethyl-3-[5-bromo-2-[3-fluoro-4-(4-methoxy-2-methylbenzoyl)-

phenylamino]phenyl]urea (Compound 123),

1-Ethyl-3-[5-bromo-2-[3-chloro-4-(2,4,5-trimethylbenzoyl)-

phenylamino]phenyl]urea (Compound 124),

1-Ethyl-3-[5-bromo-2-[3-chloro-4-(4-fluoro-2-methylbenzoyl)-

phenylamino]phenyl]urea (Compound 125),

1-Ethyl-3-[5-bromo-2-[3-fluoro-4-(2-methylbenzoyl)-

phenylamino]phenyl]urea (Compound 126),

and salts thereof with pharmaceutically acceptable acids,

hydrates and solvates.

6. (Previously Presented) A pharmaceutical composition containing as an active ingredient a compound according to claim 1 together with a pharmaceutically acceptable carrier and optionally together with a second active ingredient optionally selected from the group consisting of glucocorticoids, vitamins D's, anti-histamines, platelet activating factor (PAF) antagonists, anticolinergic agents, methyl xanthines, β-adrenergic agents, salicylates, indomethacin, flufenamate, naproxen, timegadine, gold salts, penicillamine, serum cholesterol-reducing agents, retinoids, zinc salts, and salicylazosulfapyridin (Salazopyrin).

7. (Cancelled)

8. (Currently Amended) A method for the treatment and/or prophylaxis of asthma, allergy, arthritis, including rheumatoid arthritis and spondyloarthritis, gout, atherosclerosis, chronic inflammatory bowel disease (Crohn's disease), proliferative and inflammatory skin disorders, such as psoriasis, atopic dermatitis, uveitis, septic shock, AIDS, osteoporosis and acne, ~~characterized in~~ which comprises administering to a patient suffering from at least one of said diseases an effective amount of one or more compounds according to claim 1 as an active ingredient alone, or ~~if necessary~~ optionally together with a pharmaceutically acceptable

carrier, and, optionally, a second active ingredient optionally selected from the group consisting of glucocorticoids, vitamin D's, anti-histamines, platelet activating factor (PAF) antagonists, anticolinergic agents, methyl xanthines, β-adrenergic agents, salicylates, indomethacin, flufenamate, naproxen, timegadine, gold salts, penicillamine, serum cholesterol-reducing agents, retinoids, zinc salts, and salicylazosulfapyridin (Salazopyrin).

9. (Currently Amended) A method of treatment according to claim ~~1 comprising administering to a mammal in need of systemic treatment~~ 8, wherein a suitable dose of a compound of formula I of from 0.1 to 200 mg/kg bodyweight~~, preferably a dose of from 0.2 to 50 mg/kg of mammal bodyweight~~ is administered one or more times daily.

10. (New) A method of treatment according to claim 8 wherein a suitable dose of a compound of formula I of from 0.2 to 50 mg/kg bodyweight is administered one or more times daily.

11. (New) A method for inhibiting interleukin 1β or tumour necrosis factor α secretion, which comprises administering to a mammal or patient in need thereof an effective amount of one or more compounds according to claim 1.

12. (New) A method of treatment according to claim 11, wherein interleukin 1β secretion is inhibited.

13. (New) A method of treatment according to claim 11, wherein tumour necrosis factor α secretion is inhibited.

14. (New) A method of treatment according to claim 11, wherein the compound is administered to the mammal or patient in a dosage range of from 0.1 to 200 mg/kg bodyweight one or more times daily.

15. (New) A method of treatment according to claim 11, wherein the compound is administered to the mammal or patient in a dosage range of from 0.2 to 50 mg/kg bodyweight one or more times daily.